AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALLO
  4. [SCHEDULE 13G] Allogene Therapeutics, Inc. SEC Filing

[SCHEDULE 13G] Allogene Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source:

Stock ALLO logo
Allogene Therapeutics

NASDAQ:ALLO

ALLO Rankings

#4045 Ranked by Market Cap
N/A Ranked by Dividends

ALLO Latest News

Aug 13, 2025
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
Aug 6, 2025
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Aug 1, 2025
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Jun 1, 2025
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
May 23, 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLO Latest SEC Filings

Aug 13, 2025
[10-Q] Allogene Therapeutics, Inc. Quarterly Earnings Report
Aug 13, 2025
[8-K] Allogene Therapeutics, Inc. Reports Material Event
Aug 12, 2025
[SCHEDULE 13G/A] Allogene Therapeutics, Inc. SEC Filing
Aug 8, 2025
[SCHEDULE 13G/A] Allogene Therapeutics, Inc. SEC Filing
Aug 1, 2025
[8-K] Allogene Therapeutics, Inc. Reports Material Event

ALLO Stock Data

227.48M
148.74M
17.7%
81.75%
11.86%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO